ARTICLE | Finance
Forbion leads Azafaros’ €25M series A, with rare disease vet as chair
Azafaros believes its oral dual inhibitor approach could treat lysosomal storage disorders that affect the brain
February 8, 2020 12:26 AM UTC
Updated on Feb 10, 2020 at 3:06 PM UTC
With a €25 million ($27.7 million) series A commitment, an investor syndicate led by Forbion believes Dutch start-up Azafaros can develop a dual inhibitor of glycometabolic processes to treat lysosomal storage disorders, particularly those with neuropathological effects.
Seeded in July 2018 by founding investor BioGeneration Ventures (BGV), Azafaros B.V. believes its preclinical lead program AZ-3102 -- a dual inhibitor of GCS and GBA2 -- could treat multiple lysosomal storage-related indications. ...